MRK.DE - MERCK Kommanditgesellschaft auf Aktien

XETRA - XETRA Delayed price. Currency in EUR
102.90
-0.45 (-0.44%)
At close: 5:35PM CET
Stock chart is not supported by your current browser
Previous close103.35
Open102.95
Bid103.05 x 6700
Ask103.10 x 11200
Day's range102.10 - 103.25
52-week range85.84 - 110.35
Volume689,496
Avg. volume495,108
Market cap45B
Beta (3Y monthly)0.54
PE ratio (TTM)12.93
EPS (TTM)7.96
Earnings date5 Mar 2020
Forward dividend & yield1.25 (1.21%)
Ex-dividend date2019-04-29
1y target estN/A
  • Merck KGaA CFO on M&A Hiatus, Third-Quarter Earnings
    Bloomberg

    Merck KGaA CFO on M&A Hiatus, Third-Quarter Earnings

    Nov.15 -- Marcus Kuhnert, chief financial officer of Merck KGaA, said the company will focus on integrating Versum Materials before it starts looking for a new takeover target. He spoke Nov. 14 on "Bloomberg Markets: European Open" after the firm posted third-quarter earnings.

  • Thiel Marks Palantir’s Asia Push with $150 Million Japan Venture
    Bloomberg

    Thiel Marks Palantir’s Asia Push with $150 Million Japan Venture

    (Bloomberg) -- In a rare show of public support, Palantir Technologies Inc.’s co-founder and chairman Peter Thiel pitched the power of the data-mining company during a splashy Tokyo event marking its formal entry into Asia.The billionaire entrepreneur was in Japan Monday to unveil a $150 million, 50-50 joint venture with local financial services firm Sompo Holdings Inc., Palantir Technologies Japan Co. The new company will target government and public sector customers, emphasizing health and cybersecurity initially. Like IBM Corp. and other providers, Palantir’s software pulls together a range of data provided by its customers, mining it for patterns and displaying connections in easy-to-read spiderweb-like graphics that might otherwise get overlooked.“We can learn a lot from Japan, that some of the challenges that Japan has with its aging population are the ones all countries of the West are going to have in the years ahead,” Thiel said at a briefing in Tokyo. “We hoped this can be a two-way exchange.”The push into Asia comes at a critical time for the 15-year-old company. Despite having long-term, billion-dollar contracts with BP Plc., Merck KGaA and others in more than a dozen countries worldwide, Palantir has never turned an annual profit. Under the leadership of Thiel and the management of Chief Executive Officer Alex Karp, Palantir has long emphasized engineering over sales and revenue, a focus that has shifted only this year.The company has not set a date for an initial public offering and continues to explore raising additional funding from private investors. Palantir spokeswoman Lisa Gordon told Bloomberg there are no formal conversations underway and disputed reports that Palantir is considering a deal with Softbank Group Corp. or that the company is seeking as much as $3 billion in funding at a $30 billion valuation.Valuation is a touchy subject for the Silicon Valley company. Although private investors valued Palantir in 2015 at more than $20 billion, aggressive markdowns by mutual funds and an uncertain IPO timeline have taken a toll. Palantir’s valuation has continued to tumble, with shares trading around $5 a share during the past month, according to data from secondary markets.Palantir is very close to breaking even and will end 2019 either slightly in the black or slightly in the red, Thiel said at the briefing. The company will be “significantly in the black” next year, he added.“The judgment call Palantir has made, as have many other companies in Silicon Valley post 2000, is it is often much better to build businesses in private,” Thiel said. “There is some day in the future when Palantir will go public, but we will try to stay private as long as possible.”Palantir’s public image has taken a beating in recent years. It’s attracted scrutiny from privacy advocates and protesters disturbed by the way Palantir’s software has been used by state and local law enforcement in the U.S., as well as by federal agencies like the Department of Homeland Security while implementing the controversial family separation policy at the U.S. Mexican border.Thiel himself has been a lightning rod for criticism, having helped the election of U.S. President Donald Trump in 2016, a divisive decision even within Palantir. That critique could intensify given he has pledged to support Trump’s 2020 re-election.“I envision supporting President Trump over his likely Democratic nominees,” Thiel said in Tokyo, adding he will determine the exact nature of his support as elections approach.(Updates with comments from news briefing from the third paragraph.)To contact the reporters on this story: Pavel Alpeyev in Tokyo at palpeyev@bloomberg.net;Lizette Chapman in San Francisco at lchapman19@bloomberg.netTo contact the editors responsible for this story: Edwin Chan at echan273@bloomberg.net, Vlad SavovFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Merck KGaA raises 2019 guidance after Versum takeover
    Reuters

    Merck KGaA raises 2019 guidance after Versum takeover

    German science and technology company Merck KGaA raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials in October. Merck said 2019 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, would come in between 4.23 billion euros and 4.43 billion euros (£3.82 billion), up from a previous prediction of between 4.15 billion euros and 4.35 billion euros. Shares in Merck were down 1.55% at 0828 GMT.

  • If You Had Bought MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Stock Five Years Ago, You Could Pocket A 47% Gain Today
    Simply Wall St.

    If You Had Bought MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Stock Five Years Ago, You Could Pocket A 47% Gain Today

    Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...

  • Calculating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)
    Simply Wall St.

    Calculating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of MERCK...

  • These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well
    Simply Wall St.

    These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Reuters - UK Focus

    Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane

    Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer's Xalkori drug was given the designation https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0 last year.

  • These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Is Using Debt Reasonably Well
    Simply Wall St.

    These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Is Using Debt Reasonably Well

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

  • Reuters - UK Focus

    UPDATE 2-GSK builds oncology pipeline as drug shown to help myeloma patients

    GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business. Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion last year and an agreement in February to pay up to 3.7 billion euros ($4.09 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.

  • Reuters - UK Focus

    No-deal Brexit could deepen Europe's shortage of medicines - experts

    As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.

  • Reuters - UK Focus

    UPDATE 2-GSK drug helps ovarian cancer patients live longer in late-stage study

    GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday. The company bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian cancer patients. For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co's Lynparza and Clovis Oncology's Rubraca.

  • Despite Its High P/E Ratio, Is MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Still Undervalued?
    Simply Wall St.

    Despite Its High P/E Ratio, Is MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Still Undervalued?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...

  • How Does MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Fare As A Dividend Stock?
    Simply Wall St.

    How Does MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Fare As A Dividend Stock?

    Could MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) be an attractive dividend share to own for the long haul...

  • Reuters - UK Focus

    UPDATE 2-European shares rise, spurred on by healthcare stocks

    European shares recovered from early losses to end Monday higher as gains in healthcare stocks helped head off weakness in trade-sensitive sectors like technology after the latest twist in the U.S.-China trade war. China will reportedly investigate whether FedEx Corp damaged its clients' legal rights and interests after telecoms giant Huawei said parcels intended for it were diverted. "Tensions between the U.S. and China, and the U.S. and Mexico, are still high - the highest they have been recently, so today's move might turn out to be a relief rally," David Madden, market analyst at CMC Markets UK, wrote in a note.

  • Reuters

    Merck KGaA sees currencies supporting 2019 outlook

    FRANKFURT (Reuters) - Germany's Merck KGaA, which is taking over U.S. electronic chemicals maker Versum Materials, said it expected a slight tailwind from foreign exchange effects supporting earnings growth ...

  • Based On Its ROE, Is MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) A High Quality Stock?
    Simply Wall St.

    Based On Its ROE, Is MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) A High Quality Stock?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). We'll use ROE to examine MERCK Kommanditgesells...

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more